144800-91-9

Upstream product

• 145127-35-1 3-(4-methoxytetrahydro-2H-pyran-4-yl)toluene 
• 591-17-3 meta-bromotoluene 
• 145127-34-0 3-(4-hydroxytetrahydro-2H-pyran-4-yl)toluene 

Downstream Products

• 144819-26-1 7-<<3-(4-methoxytetrahydro-2H-pyran-4-yl)phenyl>methoxy>-4-phenylnaphtho<2,3-c>furan-1(3H)-one 
• 1289485-93-3 N-(2-(benzyloxy)phenyl)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)methanesulfonamide 
• 1289485-95-5 N-(2-(benzyloxy)-4-chlorophenyl)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)methanesulfonamide 
• 1289485-97-7 N-(2-(benzyloxy)-5-chlorophenyl)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)methanesulfonamide 
• 1289485-98-8 N-(2-(benzyloxy)-5-methylphenyl)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)methanesulfonamide 
• 1289486-01-6 N-(2-(benzyloxy)-5-nitrophenyl)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)methanesulfonamide 
• 1289486-13-0 4-(3-((2-(benzyloxy)-4-chlorophenoxy)methyl)phenyl)-4-methoxytetrahydro-2H-pyran 
• 1289486-03-8 2-(benzyloxy)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl) benzyl) aniline 
• 1289486-12-9 4-(3-((2-(benzyloxy)phenoxy)methyl)phenyl)-4-methoxytetrahydro-2H-pyran 
• 1289486-06-1 2-(benzyloxy)-5-chloro-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)aniline 
• 1289486-04-9 2-(benzyloxy)-4-chloro-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl) benzyl) aniline 
• 1289486-10-7 2-(benzyloxy)-N-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl)-5-nitroaniline 
• 1289486-16-3 ethyl 3-(benzyloxy)-4-(3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyloxy)benzoate 
• 1289485-31-9 (3-(4-methoxytetrahydro-2H-pyran-4-yl)phenyl)methanesulfonylchloride 

Relevant academic research and scientific papers

Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase

Cyclooxygenase-1/2 (COX-1/2) and 5-lipoxygenase (5-LOX) are enzymes in two different pathways in the inflammatory process. In the present study, a variety of new nimesulide derivatives were synthesized through incorporation of a 5-LOX pharmacophore into nimesulide followed with some structural modifications, which were then characterized for dual enzyme inhibitors for these two types of enzymes. Their structure-activity relationships (SARs) were studied, and compound 20f was found to be an excellent dual enzyme inhibitor. Its binding conformation and interaction mode were studied with molecular docking experiments. Compound 20f could become a lead compound for further development for potential anti-inflammatory drugs.

TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

Naphthalenic Lignan Lactones as Selective, Nonredox 5-Lipoxygenase Inhibitors. Synthesis and Biological Activity of (Methoxyalkyl)thiazole and Methoxytetrahydropyran Hybrids

Combinations of structural elements found in (methoxyalkyl)thiazole 1a and methoxytetrahydropyran 2a with a naphthalenic lignan lactone produce the potent 5-lipoxygenase (5-LO) inhibitors 3 and 4.While the nature of link Y-Z has a major effect on the in v